Pivotal readout
Lilly's Taltz plus Zepbound beats Taltz alone at one year in obese psoriatic arthritis
In the 271-patient TOGETHER-PsA trial, 43.7% on the combination reached ACR50 at week 52 against 15.7% on ixekizumab alone. The week-36 primary goal, ACR50 plus at least 10% weight loss, was met by 31.7% versus 0.8%. The one-year results are exploratory, and side effects matched those already known for each drug.
- Drugixekizumab
- Drugtirzepatide
- CompanyEli Lilly and Company
- TargetInterleukin-17A
- TargetGlucagon-like peptide-1 receptor
- TrialNCT06588296
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.